# 99Tc-MDP for Thyroid-Associated Ophthalmopathy

> **NCT03948191** · PHASE4 · COMPLETED · sponsor: **Dalian University** · enrollment: 50 (actual)

## Conditions studied

- Thyroid-Associated Ophthalmopathy

## Interventions

- **DRUG:** Methylprednisolone
- **DRUG:** 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)

## Key facts

- **NCT ID:** NCT03948191
- **Lead sponsor:** Dalian University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2018-12-30
- **Final completion:** 2019-03-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03948191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03948191, "99Tc-MDP for Thyroid-Associated Ophthalmopathy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03948191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*